C-1311
C-1311 structure
|
Common Name | C-1311 | ||
|---|---|---|---|---|
| CAS Number | 138154-39-9 | Molecular Weight | 350.41400 | |
| Density | 1.32g/cm3 | Boiling Point | 605.8ºC at 760mmHg | |
| Molecular Formula | C20H22N4O2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 320.2ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
DNA-damaging imidazoacridinone C-1311 induces autophagy followed by irreversible growth arrest and senescence in human lung cancer cells.
J. Pharmacol. Exp. Ther. 346(3) , 393-405, (2013) Imidazoacridinone 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. In this study, we describe the unique sequence of cellular responses to C-1311 in human non-s... |
|
|
Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.
Drug Metab. Dispos. 41(2) , 414-21, (2013) The acridinone derivates 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) and 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) are promising antitumor agents with high activity against several experimental cellular and tumor models ... |
|
|
Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
J. Pharm. Biomed. Anal. 39(1-2) , 46-53, (2005) C1311 (5-[[2-(diethylamino)ethyl]amino]-8-hydroxyimidazo [4,5,1-de]-acridin-6-one-dihydrochloride trihydrate) is the lead compound from the group of imidazoacridinones, a novel group of rationally designed anticancer agents. The pharmaceutical development of ... |
|
|
Thermoresponsive polymeric gel as a medium for examining interactions between dsDNA and an anticancer drug.
Anal. Bioanal. Chem 392(3) , 463-9, (2008) A piece of dry N-isopropylacrylamide polymer was soaked in phosphate buffer to obtain a hydrogel which was then employed in the examination of interactions between an anticancer drug C-1311 (5-diethylaminoethyl-amino-8-hydroxyimidazoacridinone) and dsDNA. dsD... |
|
|
Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells.
Xenobiotica 41(12) , 1044-55, (2011) 5-Dimethylaminopropylamino-8-hydroxytriazoloacridinone, C-1305, being the close structural analogue of the clinically tested imidazoacridinone anti-tumour agent, C-1311, expressed high activity against experimental tumours and is expected to have more advanta... |
|
|
Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Cancer Biol. Ther. 12(7) , 586-97, (2011) Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial grow... |
|
|
The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
Int. J. Oncol. 29(6) , 1493-9, (2006) We describe a modified hollow fibre assay (HFA) for investigating the potential of novel molecules as pharmaceutical agents. In particular the assay provides drug/target interaction data that can facilitate the selection of lead compounds for further evaluati... |
|
|
Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver.
Acta Biochim. Pol. 54(4) , 831-8, (2007) The imidazoacridinone derivative C-1311 is an antitumor agent in Phase II clinical trials. The molecular mechanism of enzymatic oxidation of this compound in a peroxidase model system was reported earlier. The present studies were performed to elucidate the r... |
|
|
Similarity between enzymatic and electrochemical oxidation of 2-hydroxyacridinone, the reference compound of antitumor imidazoacridinones.
Acta Biochim. Pol. 50(2) , 515-25, (2003) The present work is part of a wide research project aimed to elucidate the mechanism of the metabolic activation of the antitumor imidazoacridinone agent C-1311 selected for clinical trials. The objectives of the investigations presented here were: (i) to exa... |
|
|
Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.
Drug Metab. Dispos. 40(9) , 1736-43, (2012) 5-Diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311 (NSC-645809), is an antitumor agent shown to be effective against breast cancer in phase II clinical trials. A similar compound, 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone, C-1305, shows ... |